达格列净对射血分数降低心衰患者门诊恶化事件的影响:DAPA-HF预先分析
DAPA-HF试验的预先分析显示,在指南推荐治疗基础上加用达格列净可降低射血分数降低心衰患者门诊心衰恶化(需口服药物强化)的风险。扩展复合终点(含门诊恶化)的发生率在安慰剂组为28.8%,达格列净组为22.2%(HR 0.73,95%CI 0.65-0.82,P<0.0001)。门诊恶化事件常见且预后重要,达格列净可显著减少此类事件。
要点
- 达格列净降低扩展复合终点风险(HR 0.73),包括门诊口服治疗强化事件。
- 门诊心衰恶化常见(8.6%患者首次事件为门诊强化治疗),且与死亡风险增加相关。
- 需治疗16例患者(中位随访18.2个月)可预防1例致命或非致命性心衰恶化。
核心结论
- 在DAPA-HF中,门诊心衰恶化事件常见且具有预后意义,达格列净可减少此类事件。
研究设计与样本
- DAPA-HF试验的预先分析,纳入NYHA II-IV级、LVEF≤40%且NT-proBNP升高的心衰患者,随机分配至达格列净或安慰剂组,共4744例。
主要发现
- 扩展复合终点(主要终点+门诊口服治疗强化)在安慰剂组发生684/2371例(28.8%),达格列净组527/2373例(22.2%),HR 0.73(95%CI 0.65-0.82),P<0.0001。
- 中位随访18.2个月,需治疗16例患者以预防1例致命或非致命性心衰恶化。
- 在4744例随机患者中,首次恶化事件为门诊治疗强化者407例(8.6%),紧急心衰静脉治疗就诊20例(0.4%),心衰住院489例(10.3%),心血管死亡295例(6.2%)。
- 调整后全因死亡风险:门诊恶化后HR 2.67(95%CI 2.03-3.52),紧急心衰就诊后HR 3.00(95%CI 1.39-6.48),心衰住院后HR 6.21(95%CI 5.07-7.62)。
临床怎么用
- 对于射血分数降低心衰患者,达格列净可减少包括门诊口服治疗强化在内的心衰恶化事件。
- 门诊心衰恶化事件提示死亡风险增加,应引起临床关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the risk of mortality and heart failure (HF) hospitalization. We examined the frequency and significance of episodes of outpatient HF worsening, requiring the augmentation of oral therapy, and the effects of dapagliflozin on these additional events. METHODS: Patients in New York Heart Association functional class II to IV, with a left ventricular ejection fraction ≤40% and elevation of NT-proBNP (N-terminal pro-B-type natriuretic peptide), were eligible. The primary outcome was the composite of an episode of worsening HF (HF hospitalization or an urgent HF visit requiring intravenous therapy) or cardiovascular death, whichever occurred first. An additional prespecified exploratory outcome was the primary outcome plus worsening HF symptoms/signs leading to the initiation of new, or the augmentation of existing, oral treatment. RESULTS: Overall, 36% more patients experienced the expanded, in comparison with the primary, composite outcome. In the placebo group, 684 of 2371 (28.8%) patients and, in the dapagliflozin group, 527 of 2373 (22.2%) participants experienced the expanded outcome (hazard ratio, 0.73 [95% CI, 0.65-0.82]; P<0.0001). Each component of the composite was reduced significantly by dapagliflozin. Over the median follow-up of 18.2 months, the number of patients needed to treat with dapagliflozin to prevent 1 experiencing an episode of fatal or nonfatal worsening was 16. Among the 4744 randomly assigned patients, the first episode of worsening was outpatient augmentation of treatment in 407 participants (8.6%), an urgent HF visit with intravenous therapy in 20 (0.4%), HF hospitalization in 489 (10.3%), and cardiovascular death in 295 (6.2%). The adjusted risk of death from any cause (in comparison with no event) after an outpatient worsening was hazard ratio, 2.67 (95% CI, 2.03-3.52); after an urgent HF visit, the adjusted risk of death was hazard ratio, 3.00 (95% CI, 1.39-6.48); and after a HF hospitalization, the adjusted risk of death was hazard ratio, 6.21 (95% CI, 5.07-7.62). CONCLUSION: In DAPA-HF, outpatient episodes of HF worsening were common, were of prognostic importance, and were reduced by dapagliflozin. Registration: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT03036124.
引用
- Docherty KF, Jhund PS, Anand I, et al. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Circulation. 2020. PMID: 32883108. doi:10.1161/CIRCULATIONAHA.120.047480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。